TP53 and lung carcinoma: Since hypoxia [8] and some RAS mutations [26] may increase drug resistance partly by favouring p53 tumor suppressor dysfunction [8], this report investigated whether hypoxia unequally induces resistance to 3-BrPA in wt p53 tumor cells like MelJuso melanoma harbouring (Q61L)-mutant NRAS and wt BRAF, C8161 melanoma with (G12D)-mutant KRAS (G464E)-mutant BRAF and A549 lung carcinoma with a KRAS (G12S)-mutation.